23andMe competitor claims direct-to-consumer cancer risk screening produces 'false negatives'.

23andMe competitor claims direct-to-consumer cancer risk screening produces "false negatives" These at-home DNA testing kits are a booming healthcare business with companies like 23andMe, MyHeritage and now Ancestry offering genetic health testing. But researchers at medical genetics company Invitae say health reports from limited DTC genetic tests can provide consumers with a false sense of security. [Extracted from the article]

Copyright of FierceHealthcare is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)